TABLE 3.
Univariate and multivariate analyses of the effects of clinical characteristics on PFS and OS
| Characteristics | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Age (< 60 years vs. ≥ 60 years) | 0.9 (0.6–1.3) | 0.505 | – | – | 1.2 (0.7–2.0) | 0.541 | – | – |
| Sex (male vs. female) | 1.2 (0.7–2.1) | 0.453 | – | – | 1.2 (0.6–2.3) | 0.676 | – | – |
| ECOG performance status (0–1 vs. 2) | 2.3 (1.5–3.4) | <0.001 | 1.9 (1.3–3.0) | 0.002 | 3.0 (1.7–5.2) | <0.001 | 2.4 (1.3–4.5) | 0.005 |
| Alcohol use (current or previous vs. never) | 1.1 (0.8–1.7) | 0.476 | – | – | 1.0 (0.6–1.7) | 0.948 | – | – |
| Lung metastasis (yes vs. no) | 1.5 (1.0–2.2) | 0.049 | 1.2 (0.8–1.9) | 0.298 | 2.0 (1.2–3.5) | 0.007 | 1.2 (0.7–2.3) | 0.429 |
| Lymph nodes metastasis (yes vs. no) | 1.0 (0.7–1.4) | 0.861 | – | – | 1.3 (0.8–2.3) | 0.262 | – | – |
| Bone metastasis (yes vs. no) | 1.4 (0.7–3.0) | 0.285 | – | – | 1.3 (0.4–3.8) | 0.665 | – | – |
| Peritoneum metastasis (yes vs. no) | 2.0 (0.9–4.6) | 0.024 | 2.4 (1.3–4.5) | 0.008 | 2.8 (1.0–8.1) | 0.003 | 3.0 (1.4–6.7) | 0.007 |
| Intra‐abdominal implantation (yes vs. no) | 0.9 (0.4–1.9) | 0.760 | – | – | 0.6 (0.2–2.0) | 0.509 | – | – |
| Adrenal gland metastasis (yes vs. no) | 1.4 (0.5–3.8) | 0.376 | – | – | 1.8 (0.6–5.8) | 0.205 | – | – |
| Child‐Pugh stage (A vs. B) | 1.9 (1.1–3.2) | 0.004 | 1.5 (0.9–2.4) | 0.116 | 3.3 (1.5–7.4) | <0.001 | 2.6 (1.3–4.9) | 0.005 |
| BCLC stage (B vs. C) | 1.2 (0.7–2.2) | 0.474 | – | – | 3.6 (1.6–8.1) | 0.056 | – | – |
| Alpha‐Fetoprotein, IU/ml (<400 vs. ≥400) | 1.1 (0.7–1.6) | 0.641 | – | – | 2.1 (1.2–3.6) | 0.004 | 2.0 (1.1–3.4) | 0.021 |
| Macrovascular invasion (yes vs. no) | 0.7 (0.5–1.0) | 0.064 | – | – | 1.9 (1.1–3.2) | 0.019 | 1.7 (0.9–3.1) | 0.079 |
| Viral status (hepatitis B vs. uninfected) | 1.5 (0.8–2.8) | 0.240 | – | – | 0.7 (0.3–1.9) | 0.465 | – | – |
| Liver cirrhosis (yes vs. no) | 1.2 (0.8–1.9) | 0.399 | – | – | 0.7 (0.3–1.3) | 0.164 | – | – |
| Previous immunotherapy (yes vs. no) | 2.0 (1.0–4.3) | 0.011 | 2.6 (1.4–4.5) | 0.001 | 3.0 (1.1–8.5) | <0.001 | 3.2 (1.5–6.6) | 0.002 |
| Previous antiangiogenic therapy (yes vs. no) | 1.0 (0.7–1.5) | 0.784 | – | – | 1.1 (0.6–1.9) | 0.746 | – | – |
| Treatment systemic lines (0 vs. ≥1) | 1.3 (0.9–1.9) | 0.164 | – | – | 1.3 (0.7–2.1) | 0.395 | – | – |
| Previous surgery (yes vs. no) | 0.8 (0.5–1.1) | 0.142 | – | – | 0.8 (0.5–1.3) | 0.311 | – | – |
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; vs., versus.